ADP-A2M4 — التعريف

ADP-A2M4 is a genetically modified autozomal T cell receptor (TCR) treatment aimed at MAGE-A4 antigen in certain types of cancer. This experimental immunotherapy strengthens the immune response to tumor cells by giving the patient the ability to recognize MAGE-A4 to their T cells. In clinical trials, the activity is investigated especially in synoval sarcoma and other solid tumors.